These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 21370595)
1. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595 [TBL] [Abstract][Full Text] [Related]
2. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402 [TBL] [Abstract][Full Text] [Related]
3. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks. Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
5. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses. Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232 [TBL] [Abstract][Full Text] [Related]
6. Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer. Shan L; Chen YA; Davis L; Han G; Zhu W; Molina AD; Arango H; LaPolla JP; Hoffman MS; Sellers T; Kirby T; Nicosia SV; Sutphen R PLoS One; 2012; 7(10):e46846. PubMed ID: 23082132 [TBL] [Abstract][Full Text] [Related]
7. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients. Bastani A; Asghary A; Heidari MH; Karimi-Busheri F Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884 [TBL] [Abstract][Full Text] [Related]
9. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727 [TBL] [Abstract][Full Text] [Related]
10. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055 [TBL] [Abstract][Full Text] [Related]
13. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor. Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233 [TBL] [Abstract][Full Text] [Related]
14. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680 [TBL] [Abstract][Full Text] [Related]
15. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854 [TBL] [Abstract][Full Text] [Related]
16. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557 [TBL] [Abstract][Full Text] [Related]
17. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084 [TBL] [Abstract][Full Text] [Related]
18. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214 [TBL] [Abstract][Full Text] [Related]
19. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911 [TBL] [Abstract][Full Text] [Related]
20. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]